Ex-Dividend Reminder: STERIS, Assurant and Kemper

STERIS (STE), Assurant (AIZ) and Kemper (KMPR) trade ex-dividend on 2/17/2026 with quarterly payouts of $0.63 (STE, payable 3/19/26), $0.88 (AIZ, payable 3/30/26) and $0.32 (KMPR, payable 3/3/26). The story notes implied single-day price impacts of roughly -0.26% for STE (based on a $244.22 share price), -0.41% for AIZ and -0.99% for KMPR, and annualized yields of approximately 1.03% (STE), 1.64% (AIZ) and 3.95% (KMPR); intraday moves reported were STE +0.3%, AIZ -0.7% and KMPR -0.2%.

Analysis

Market structure: The announced ex-dividends are mechanically small — STE -0.26%, AIZ -0.41%, KMPR -0.99% — so short-term price moves will be dominated by cash-flow timing and dividend-capture flows rather than fundamental re-rating. Insurers (AIZ, KMPR) are the primary beneficiaries if bond yields rise because investment spread expansion improves earnings; STERIS (STE) is less rate-sensitive and benefits from stable hospital capex and procedural volumes. Cross-asset: a 25–50bp move in the 10yr materially shifts insurer EPS (±5–10% range over 12 months) and increases option implied-volatility around ex-dividend and earnings dates.

Risk assessment: Immediate risk is short-term pinning and option gamma around 2/17–3/3; watch elevated volume and bid/ask widening for 1–3 trading days. Tail risks include reserve shocks or adverse loss development at insurers (combined ratio +200bps) and product recalls or supply-chain outage at STE; these would force dividend suspension and >20% downside. Key hidden dependency: insurer profitability is levered to fixed-income yields and reserve discounting assumptions — a >50bp drop in yield vs current level would reverse the investment thesis over 6–12 months.

Trade implications: Tactical income plays beat buy-and-hold for STE given its 1.03% annualized yield — prefer sell-write strategies post-ex-div; for KMPR (3.95% yield) consider modest core long exposure because higher yields or stable rates are a tailwind. Relative-value: long KMPR vs short AIZ if 10yr > current +25bps and KMPR/AIZ valuation spread >150bps; use 30–90 day options to harvest premium and define risk. Entry/exit: enter 3–7 days after ex-dividend to avoid microstructure noise; target 3–9 month horizon.

Contrarian angles: The market likely underprices the rate-leverage in KMPR’s income book — dividend yield ~4% may represent an understated upside if 10yr moves +50bps, producing 10–20% EPS lift over 12 months. Conversely STE’s low yield and procedural exposure mean dividend-focused buyers may be underexposed to operational risk; the ex-div dip is often fully mean-reverted within 1–3 weeks, creating short-term arbitrage. Unintended consequence: dividend funds selling to rebalance on ex-date can create transient liquidity gaps — use those windows to layer entries rather than full-sized buys.

Key Decisions for Investors

• Establish a modest 1.5–2.5% long position in KMPR (Kemper) within 3–7 trading days after the 2/17 ex-div date; set a 3–9 month target of +12–20% and a stop-loss at -10% or if company reports combined-ratio deterioration >200bps QoQ.
• If you own STE (STERIS), implement a sell-write: sell 30-day calls 1–2% OTM on up to 50% of your position immediately after the 2/17 ex-div to capture ~0.3–0.6% premium; roll or re-assess post-earnings (next 60–90 days).
• Initiate a relative-value pair trade: long KMPR 1.5% vs short AIZ 1.5% if the 10yr UST yield rises by >25bps from current levels or KMPR/AIZ valuation spread >150bps; close after 3 months or if KMPR underperforms by 5% vs AIZ or combined-ratio news >150bps.
• Use options to lower entry cost on KMPR: sell cash-secured 60-day puts 2–4% below current price representing no more than 3% of portfolio capital to collect premium and acquire stock at a discount; cap assignment exposure and close if implied vol increases >40% or claims guidance worsens.